<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912495</url>
  </required_header>
  <id_info>
    <org_study_id>NL44825.078.13</org_study_id>
    <nct_id>NCT01912495</nct_id>
  </id_info>
  <brief_title>Dutch Acute HCV in HIV Study (DAHHS)</brief_title>
  <acronym>DAHHS</acronym>
  <official_title>Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slotervaart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective open label proof of concept feasibility interventional clinical trial in which 60
      acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in
      addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds at
      week 4.

      The primary hypothesis of this study is that the subset of patients with a Rapid Viral
      Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and
      ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The outcome is a number of the patients with an undetectable Hepatitis C Virus (HCV) RNA at week 4 that have an undetectable HCV RNA 12 weeks after end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR 12 Weeks After the End of All Therapy in the Entire Study Population (With or Without RVR4).</measure>
    <time_frame>12 weeks</time_frame>
    <description>The outcome is a number of all patients who started treatment having an undetectable HCV RNA 12 weeks after the end of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 12 Weeks After End of Therapy in Patients With Already a RVR at Week 1.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients who were undetectable for HCV at week one that had an undetectable HCV RNA load 12 weeks after the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 12 Weeks After End of Therapy in Patients That Started Therapy ≤12weeks After the Presumed HCV Infection Date Versus Those After 12 Weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients having a undetectable HCV RNA 12 weeks after the end of treatment in the group patients that was treated within 12 week of calculated transmission date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations of Biomarkers by Therapy Induced Viral Eradication: Viral Sequencing, Mutation Analysis, Gene Expression Analysis, and RNA Analysis.</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Treatment Related (Serious) Adverse Events ((S)AE) and Treatment Discontinuation for (S)AE.</measure>
    <time_frame>72 weeks</time_frame>
    <description>only serious adverse events are recorded in this secondary endpoint</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Boceprevir, peginterferon ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <arm_group_label>Boceprevir, peginterferon ribavirin</arm_group_label>
    <other_name>Victrelis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented recent HCV genotype 1 infection (≤26 weeks old at the time of the baseline
             visit) according to definition mentioned below.

          2. Plan to start a Standard Of Care therapy for acute HCV consisting of 24 weeks of
             Peginterferon + Ribavirin. HCV RNA plasma viral load at screening &gt;1000 IU/ml.

          3. A previously performed HCV RNA plasma measurement can be used for screening if &lt;4
             weeks old.

          4. On HAART at the time of screening.

          5. Minimum age 18 years.

        Exclusion Criteria:

          1. Disallowed co-medication that cannot be stopped or replaced: Several potentially
             life-threatening drug-drug interactions (DDI) are possible when boceprevir is combined
             with other drugs. Therefore ALL co-medication, including over-the-counter drugs should
             be checked for potential DDI with DDI table in the Dutch summary of product
             characteristics (SPC, appendix A). If the co-medication is not mentioned in the SPC
             DDI table, www.HCV-druginteractions.org should be used.

          2. Contraindications for the use of full dose of peginterferon alpha-2b or ribavirin:
             neutrophils &lt;0,75×109/l or thrombocytes &lt; 100.000×109/l or a Hb &lt;6.2mmol/L, creatinine
             clearance &lt;50ml/min).

          3. History of liver cirrhosis or &gt;F1 fibrosis on fibroscan. Inclusion of patients with a
             chronic well-controlled HBV (HBV-DNA below the limit of detection) with tenofovir,
             lamivudine or emtricitabine therapy is allowed if fibroscan excludes &gt;F1 fibrosis.
             Fibroscan reports &lt;2 years old can be used for screening. Fibroscan is not required
             for other patients at screening.

          4. HAART was started &lt;4 weeks before baseline visit.

          5. Inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse
             transcriptase inhibitors + Raltegravir (Isentress®) 400mg BID or rilpivirine 25mg QD
             or atazanavir (Reyataz®) 300mg QD + ritonavir (Norvir®) 100mg QD.

          6. Patient that virologically failed HAART in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Rijnders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud UMCN</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <results_first_submitted>December 7, 2015</results_first_submitted>
  <results_first_submitted_qc>March 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2016</results_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Bart Rijnders</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Boceprevir</title>
          <description>12 week Boceprevir, Peginterferon and Ribavirin in RVR4 group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57">8 patients had only screening visit, total enrollment: 65</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Boceprevir/Peginterferon/Ribavirin</title>
          <description>Boceprevir with Peginterferon and Ribavirin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="34" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population.</title>
        <description>The outcome is a number of the patients with an undetectable Hepatitis C Virus (HCV) RNA at week 4 that have an undetectable HCV RNA 12 weeks after end of treatment.</description>
        <time_frame>12 weeks</time_frame>
        <population>41 patients had a RVR4</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir, Peginterferon and Ribavirin</title>
            <description>12 week Boceprevir, Peginterferon and Ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Viral Response(SVR) 12 Weeks of Follow up After the End of All Therapy for the Rapid Viral Response at Week 4(RVR4) Population.</title>
          <description>The outcome is a number of the patients with an undetectable Hepatitis C Virus (HCV) RNA at week 4 that have an undetectable HCV RNA 12 weeks after end of treatment.</description>
          <population>41 patients had a RVR4</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR 12 Weeks After the End of All Therapy in the Entire Study Population (With or Without RVR4).</title>
        <description>The outcome is a number of all patients who started treatment having an undetectable HCV RNA 12 weeks after the end of therapy</description>
        <time_frame>12 weeks</time_frame>
        <population>Total intention to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir, Peginterferon and Ribavirin</title>
            <description>12 week boceprevir, peginterferon and ribavirin in intention to treat group</description>
          </group>
        </group_list>
        <measure>
          <title>SVR 12 Weeks After the End of All Therapy in the Entire Study Population (With or Without RVR4).</title>
          <description>The outcome is a number of all patients who started treatment having an undetectable HCV RNA 12 weeks after the end of therapy</description>
          <population>Total intention to treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR 12 Weeks After End of Therapy in Patients With Already a RVR at Week 1.</title>
        <description>The number of patients who were undetectable for HCV at week one that had an undetectable HCV RNA load 12 weeks after the end of treatment</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients having a rapid viral response at week 4 had a sustained viral response at 12(SVR12) weeks after treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir, Peginterferon and Ribavirin</title>
            <description>12 week Boceprevir, Peginterferon and Ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>SVR 12 Weeks After End of Therapy in Patients With Already a RVR at Week 1.</title>
          <description>The number of patients who were undetectable for HCV at week one that had an undetectable HCV RNA load 12 weeks after the end of treatment</description>
          <population>All patients having a rapid viral response at week 4 had a sustained viral response at 12(SVR12) weeks after treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR 12 Weeks After End of Therapy in Patients That Started Therapy ≤12weeks After the Presumed HCV Infection Date Versus Those After 12 Weeks.</title>
        <description>The number of patients having a undetectable HCV RNA 12 weeks after the end of treatment in the group patients that was treated within 12 week of calculated transmission date.</description>
        <time_frame>12 weeks</time_frame>
        <population>5 patients were treated within 12 weeks after calculated transmission date. All other patients were treated between 12 and 26 weeks after calculated transmission date.</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir Peginterferon Ribavirin</title>
            <description>12 week Boceprevir peginterferon and ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>SVR 12 Weeks After End of Therapy in Patients That Started Therapy ≤12weeks After the Presumed HCV Infection Date Versus Those After 12 Weeks.</title>
          <description>The number of patients having a undetectable HCV RNA 12 weeks after the end of treatment in the group patients that was treated within 12 week of calculated transmission date.</description>
          <population>5 patients were treated within 12 weeks after calculated transmission date. All other patients were treated between 12 and 26 weeks after calculated transmission date.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alterations of Biomarkers by Therapy Induced Viral Eradication: Viral Sequencing, Mutation Analysis, Gene Expression Analysis, and RNA Analysis.</title>
        <time_frame>72 weeks</time_frame>
        <population>data were not collected during this study</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir Peginterferon Ribavirin</title>
            <description>Boceprevir peginterferon and ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Alterations of Biomarkers by Therapy Induced Viral Eradication: Viral Sequencing, Mutation Analysis, Gene Expression Analysis, and RNA Analysis.</title>
          <population>data were not collected during this study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Treatment Related (Serious) Adverse Events ((S)AE) and Treatment Discontinuation for (S)AE.</title>
        <description>only serious adverse events are recorded in this secondary endpoint</description>
        <time_frame>72 weeks</time_frame>
        <population>57 patients started treatment and were at risk</population>
        <group_list>
          <group group_id="O1">
            <title>Boceprevir, Peginterferon and Ribavirin</title>
            <description>12 week boceprevir, peginterferon and ribavirin in intention to treat group</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Treatment Related (Serious) Adverse Events ((S)AE) and Treatment Discontinuation for (S)AE.</title>
          <description>only serious adverse events are recorded in this secondary endpoint</description>
          <population>57 patients started treatment and were at risk</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Boceprevir</title>
          <description>12 week Boceprevir, Peginterferon and Ribavirin in RVR4 group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>One myocardial infarction in a patient with a high-grade left anterior descending artery stenosis that was stented uneventfully (hemoglobin (Hb) 8∙7 mmol/L at the time of the infarction).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>One anemia (Hb 5·1 mmol/L) for which a transfusion was given and the ribavirin dose was decreased.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <description>One suspected transient ischemic attack that resolved spontaneously and with normal MRI findings (Hb 6∙6 mmol/L)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 1 anemia was observed in 83%</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <description>grade 2 anemia was observed in 12%</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>B.J.A.Rijnders</name_or_title>
      <organization>Erasmus MC</organization>
      <phone>0031107034529</phone>
      <email>b.rijnders@erasmusmc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

